Stereotaxis (STXS) Q2 2026 earnings review
Proprietary Catheters Ignite, But the Cash Clock is Ticking
Stereotaxis is navigating a turbulent transition. Total Q2 revenue dropped 13% YoY to $7.67M, dragged down by a 51% collapse in capital system sales. However, the underlying business model is Reversing from decline to growth: proprietary robotic catheter revenue surged 270% sequentially to over $1M, successfully counteracting the painful wind-down of legacy Johnson & Johnson catheters. Management insists this is a 'commercial inflection point' and guided for aggressive H2 acceleration. Yet, with a fragile cash balance of just $10.5M and a steady quarterly burn of $3.7M, execution must be flawless to reach their promised H1 2027 profitability without painful shareholder dilution.
🐂 Bull Case
The proprietary MAGiC catheter recorded >$1M in sales, driving total recurring revenue up to $6.2M (from $5.0M in Q1). High recurring gross margins (66%) validate the strategy to capture higher revenue per procedure.
The first US hospital purchased the GenesisX robot, and multiple Synchrony digital operating rooms were sold. This expanded product suite increases the total addressable market and average account value.
🐻 Bear Case
Cash dwindled to $10.5M while Q2 FCF burn remained stubbornly Stable at $3.7M. Without an immediate injection of capital or a flawless H2 revenue ramp, the company faces severe liquidity risks before its H1 2027 profitability target.
Despite management's positive commentary on momentum, Q2 capital equipment sales fell 51% YoY to just $1.5M. The $3M per quarter H2 guidance demands a rapid turnaround in actual deal closures.
⚖️ Verdict: ⚪
Neutral. The commercial traction of proprietary catheters is a genuine breakthrough that validates years of R&D. However, the dangerously thin balance sheet casts a long shadow over the growth narrative, making the stock highly speculative until funding is secured.
Key Themes
MAGiC Catheter Ramp is Accelerating
The cornerstone of Stereotaxis' turnaround is finally generating material numbers. Robotic catheter revenue surpassed $1M in Q2, growing 270% sequentially. This rapid adoption is successfully absorbing the headwind of the legacy J&J catheter wind-down, pushing recurring revenue back into YoY growth ($6.2M vs $5.8M) and driving a healthy 66% recurring gross margin.
GenesisX & Synchrony Launch Momentum
The new capital equipment ecosystem is securing early wins. The company secured its first US GenesisX robotic system purchase (to be installed this fall) and sold multiple Synchrony digital operating room systems following its April FDA clearance. This proves willingness from hospitals to adopt the updated, less structurally-invasive technology.
Robocath Acquisition Expands the Platform
Stereotaxis completed the acquisition of Robocath, a move designed to strengthen its robotic leadership across the full spectrum of endovascular procedures (coronary and stroke). While integration costs will impact OpEx, it fundamentally expands the company's TAM beyond electrophysiology.
Cash Runway is Reaching Critical Levels
The company ended Q2 with $10.5M in cash and zero debt, while generating negative FCF of $3.7M. This trajectory implies less than three quarters of runway. Management claims they can execute their strategy without 'substantial dilution', but the mathematical reality suggests non-dilutive funding or a highly accretive capital raise is urgently required.
System Sales Contraction Contradicts Momentum Narrative
Management painted a picture of 'accelerating commercial adoption', yet Q2 system revenue Decelerated sharply, falling 51% YoY to $1.5M due to a lack of system deliveries. While pipeline indications are strong, the actual printed revenue shows a severe lag in capital equipment deal closures.
Macro Friction and Supply Chain Pressures
Management noted that overall procedure volumes remain under 'general procedural pressure from limited catheter supply.' As the company transitions accounts from J&J supply to their own MAGiC catheters, supply chain friction acts as a dampener on near-term recurring revenue realization, exposing the company to hospital operational constraints.
Other KPIs
Total OpEx increased YoY from $8.6M, driven entirely by $2.5M in non-cash charges (stock comp, Robocath contingent earnout adjustments, and intangible amortization). Adjusted operating expenses were $6.6M, remaining Stable YoY, indicating management is strictly controlling core cash expenses to preserve the runway.
Margins reflect a tale of two segments. Recurring revenue posted a strong 66% gross margin, benefiting from the high-margin proprietary catheter mix. Conversely, system gross margin compressed to an anemic 29% due to low fixed-cost absorption from only $1.5M in capital sales.
Guidance
Accelerating dramatically from the $6.2M base in Q2. This implies 13% sequential growth in Q3 and another 14% in Q4, driven entirely by methodical manufacturing and delivery increases for the MAGiC catheter. If achieved, this definitively proves the new recurring revenue model.
Reversing the slump seen in Q1 ($1.3M) and Q2 ($1.5M). Reaching $3.0M per quarter requires immediate execution on the GenesisX and Synchrony backlogs that management claims are building.
Management firmly staked a target to halt the cash burn by H1 2027. Reaching this milestone will rely on scaling total quarterly revenues well past the $11M-$12M mark while holding adjusted OpEx flat.
Key Questions
Bridging the Cash Gap
With $10.5M in cash, a $3.7M quarterly burn rate, and FCF profitability not expected until H1 2027, the math does not close without capital. What specific non-dilutive financing avenues or operational levers are being actively pursued to avoid 'substantial dilution'?
System Sales Pipeline Visibility
System revenue fell to $1.5M in Q2, yet guidance calls for a rapid step-up to $3.0M in both Q3 and Q4. How much of this $6M H2 forecast is currently sitting in a signed, non-cancellable backlog versus requiring new deals to close in-quarter?
Robocath Financial Impact
With the Robocath acquisition now complete, what is the anticipated sequential impact on operating expenses in Q3, and when do you expect the integration to yield material top-line synergies in endovascular interventions outside of electrophysiology?